Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-FLOAT: gFOLFOXIRITAX in Untreated Advanced Upper GI Adenocarcinomas
NCT04361708Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- May 2020
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), gastroesophageal junction adenocarcinoma, cholangiocarcinoma (CCA) and 2 more (3 arms), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 1 month. Started May 2020; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)gastroesophageal junction adenocarcinomacholangiocarcinoma (CCA)gallbladder adenocarcinomaampullary carcinoma
Beyond the preview
Go deeper on NCT04361708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361708.